BioScale Secures $25M for Commercialization of Acoustic-Based Protein Analytics System
June 18, 2010
BioScale Secures $25M for Commercialization of Acoustic-Based Protein Analytics System
The system, which is the eight-year-old company's first product release, uses BioScale's proprietary Acoustic Membrane MicroParticle, or AMMP, technology to offer label-free, non-optical protein detection and quantitation.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Millennium Adopts Bioscale's ViBE Platform as Part of its Drug Development Workflow
January 14, 2011 / ProteoMonitor - Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Movers & Shakers
October 15, 2010 / ProteoMonitor - Building Evidence for Potential of Acoustic Assays, BioScale Demos MAPK Pathway Analysis at AACR
April 6, 2012 / ProteoMonitor